1.纤维蛋白溶酶原
2.血纤维蛋的溶酶原
3.前纤维蛋白溶酶
4.纤维蛋白溶解原
5.血浆酶原
1.纤维蛋白溶酶原
2.血纤维蛋的溶酶原
3.前纤维蛋白溶酶
4.纤维蛋白溶解原
5.血浆酶原
1.the inactive precursor of plasmin
1.Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论:糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
2.abstract: Objective To investigate the plasminogen activator inhibitor changes in patients with diabetic nephropathy.
目的:探讨糖尿病肾病患者血浆纤溶酶原激活物抑制物的变化。
3.Recombinant tissue-type plasminogen activator (r-TPA) was also used when clinically indicated.
临床上有指征时也可应用重组组织型纤溶酶原激活剂。
4.Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.
急性缺血性卒中患应用重组组织纤溶酶原激活剂治疗的效用成本:一项系统性回顾
5.The abnormal activity of tissue-type plasminogen activator(t-PA) is the most risk factor of prethrombotic state of cardiovascular diseases.
组织型纤溶酶原激活物(tPA)活性异常是心血管疾病血栓前状态的最危险因素。
6.Plasminogen has been immobilized onto a segmented polyurethane containing amino groups, using glutaraldehyde as coupling agent.
纤溶酶原已被固定在一个分割的含氨基酸组,用偶联剂戊二醛聚氨酯。
7.abstract: Objective: To discuss the clinical value of detecting blood plasminogen activator and inhibitor in cancer patients.
目的:探讨恶性肿瘤患者血液纤溶酶原激活剂与抑制剂检测的临床应用价值。
8.THE EXPRESSION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN ORAL SQUAMOUS CELL CARCINOMA.
尿激酶受体在口腔鳞癌中的表达。
9.HMGB1 plays roles in activation of plasminogen and matrix metalloproteases, reorganization of cytoskeleton.
HMGB1与纤维蛋白酶原、基质金属蛋白酶的活化、细胞骨架重组等有关。
10.A drug called tissue plasminogen activator -- tPA -- dissolves clots and restores blood flow.
而一种称为组织纤维蛋白溶酶原激活物(tPA)的药物可以溶解血块,并恢复血液流通。